

Resource Summary Report

Generated by NIF on Sep 21, 2026

University of Virginia School of Medicine Biorepository and Tissue Research Core Facility

RRID:SCR_022971

Type: Tool

Proper Citation

University of Virginia School of Medicine Biorepository and Tissue Research Core Facility
(RRID:SCR_022971)

Resource Information

URL: <https://med.virginia.edu/biorepository-and-tissue-research-facility/>

Proper Citation: University of Virginia School of Medicine Biorepository and Tissue Research Core Facility (RRID:SCR_022971)

Description: Core is involved in procurement and processing of human tissue and other biospecimens for basic, translational, and clinical research. Provides laboratory support services for clinical trials, tissue samples from remnant surgical resection and autopsy specimens linked to clinicopathologic data while maintaining patient confidentiality. Provides biorepository of human specimens. Offers advanced histology services including multi color immunohistochemistry, in situ hybridization, tissue microarrays, slide scanning, computerized image analysis, NanoString spatial profiling.

Synonyms: Biorepository & Tissue Research Facility, University of Virginia School of Medicine Biorepository & Tissue Research Facility

Resource Type: access service resource, core facility, service resource

Keywords: USEDit, ABRF

Resource Name: University of Virginia School of Medicine Biorepository and Tissue Research Core Facility

Resource ID: SCR_022971

Alternate IDs: ABRF_1629

Alternate URLs: <https://coremarketplace.org/?FacilityID=1629&citation=1>

Record Creation Time: 20221117T050202+0000

Record Last Update: 20260919T195953+0000

Ratings and Alerts

No rating or validation information has been found for University of Virginia School of Medicine Biorepository and Tissue Research Core Facility.

No alerts have been found for University of Virginia School of Medicine Biorepository and Tissue Research Core Facility.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Ninmer EK, et al. (2026) Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC). Journal for immunotherapy of cancer, 14(3).

Byrd EE, et al. (2026) Methanogenic archaea bolster mucosal homeostasis and protect from colitis. bioRxiv : the preprint server for biology.

Berry K, et al. (2026) Histologic Heterogeneity of Metastases in Clear Cell Renal Cell Carcinoma with Sarcomatoid Differentiation. Journal of clinical medicine, 15(10).

Cobb DA, et al. (2026) $\gamma\delta$ CAR-T Cells Simultaneously Targeting Tumor and Metastases Produce Highly Effective Control in Preclinical Models of Melanoma and Triple-Negative Breast Cancer. Molecular cancer therapeutics, 25(7), 1181.

Rodrigues-Jesus MJ, et al. (2026) Multi-strain Clostridioides difficile infection: Increased detection and clinical implications. The Journal of infection, 93(2), 106800.

Marques FMS, et al. (2026) CSPG4 Mediates Inflammatory, Cell Death, and Senescence Responses in Enteric Glia Exposed to Clostridioides difficile Toxins. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(8), e71806.

Xie Z, et al. (2026) A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastoma. Science translational medicine, 18(834), eadt1211.

Demir ZEF, et al. (2026) Multimodal PET Defines a 'Goldilocks' Thermal Window for Focused Ultrasound Ablation and Immunotherapy Combinations. bioRxiv : the preprint server for biology.

Yadav N, et al. (2025) Synergistic activity of simvastatin and irinotecan chemotherapy against glioblastoma converges on TGF- β signaling. *Journal of neuro-oncology*, 174(3), 621.

Barnes RW, et al. (2025) LAG3+ CD8+ T cell Subset Drives HR+/HER2- Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell Therapy. *bioRxiv : the preprint server for biology*.

Marohl T, et al. (2025) PCSK5M452I is a recessive hypomorph exclusive to MCF10DCIS.com cells. *bioRxiv : the preprint server for biology*.

Nicklow E, et al. (2025) Exploration of biomaterial-tissue integration in heterogeneous microporous annealed particle scaffolds in subcutaneous implants over 12 months. *Acta biomaterialia*, 196, 183.

Obiorah IE, et al. (2025) Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with RUNX1 germline mutation. *Leukemia & lymphoma*, 66(4), 797.

Hanson GF, et al. (2025) A flexible systems analysis pipeline for elucidating spatial relationships in the tumor microenvironment linked with cellular phenotypes and patient-level features. *Frontiers in immunology*, 16, 1642527.

Marohl T, et al. (2025) PCSK5M452I is a recessive hypomorph exclusive to MCF10DCIS.com cells. *Molecular cancer research : MCR*.

Wei X, et al. (2025) PRMT5 Identified as a Viable Target for Combination Therapy in Preclinical Models of Pancreatic Cancer. *Biomolecules*, 15(7).

Barnes RW, et al. (2025) LAG3+ CD8+ T cell subset drives HR+/HER2- breast cancer reduction in bispecific antibody armed activated T cell therapy. *Journal of immunology* (Baltimore, Md. : 1950).

Hsu J, et al. (2024) Protocol for iterative indirect immunofluorescence imaging in cultured cells, tissue sections, and metaphase chromosome spreads. *STAR protocols*, 5(3), 103190.

Wessel RE, et al. (2024) Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer. *Journal for immunotherapy of cancer*, 12(9).

Fleming C, et al. (2024) The IL-33/ST2 signaling axis drives pathogenesis in acute SARS-CoV-2 infection. *bioRxiv : the preprint server for biology*.